The long term outlook remains favorable. Organic revenue growth is likely to be sustained at a 20%-25% rate well into the decade. A simulation based joint venture promises additional impetus. And the cash horde obtained from the offering could be applied towards accretive acquisitions. Until those inflection points are realized these shares may trend in a sideways manner, though. Downside risk is limited by Healthstream's own appeal as a potential takeover candidate.
( Click on Table to Enlarge )